Study of the mutagenic effect of the Betamide drug

The tested Betamide drug is an amide of betulonic acid, obtained as a result of chemical modification of the triterpenoid betulin isolated from birch bark. The drug has antioxidant, hepatoprotective, anti-inflammatory, antimetastatic and antitumor activity. The drug is supposed to be used in the treatment of cancer. Experimental studies were carried out on male and female C57/BL/6 mice free from specific pathogens (SPF). The drug was administered once intragastrically at doses of 2000 mg/kg, 1000 mg/kg and 500 mg/kg. It turned out that the maximum dose of 2000 mg/kg in males causes a decrease in the mitotic activity of bone marrow cells. It has been established that the drug in none of the studied doses has the ability to induce mutations in somatic cells. The maximum dose studied produced a small antimutagenic effect. In males, it is expressed in a reduced proportion of cells with multiple aberrations. For females treated with Betamide at a dose of 2000 mg/kg, there was a significant decrease in the total number of cells with disorders compared to the control.